Clinical Data Transparency in Device Trials

Abstract

Clinical data transparency in medical device trials has moved from aspirational principle to regulatory requirement over the past decade, driven by a convergence of clinical research ethics reform, public expectations for research accountability, and evidence that selective reporting of trial results systematically distorts the device evidence base available to clinicians, regulators, and patients. The transparency requirements now codified in EU MDR, FDA 21st Century Cures Act provisions, and ICMJE authorship standards represent substantial progress, but the practical implementation of transparency across device trial categories remains uneven: device trials are historically less complete in registration, results posting, and individual patient data sharing than pharmaceutical trials, and the reasons for the gap span regulatory framework differences, industry practice conventions, and structural differences in device clinical development. This study presents the Clinical Data Transparency Assessment Framework (CDTAF), evaluating five transparency implementation approaches -- registry-based transparency per ClinicalTrials.gov and EU CTIS (REG-TRN), clinical study report public summary disclosure (CSR-PSD), individual patient data sharing platforms (IPD-SP), real-time data access portals with privacy-preserving analytics (RTA-PPA), and blockchain-based immutable trial record systems (BC-ITR) -- across four device trial contexts: pivotal premarket trials, post-market clinical follow-up studies, investigator-initiated device research, and multi-device comparative effectiveness studies. Performance was scored using the Transparency Effectiveness Score (TES), a weighted composite of disclosure completeness (0.25), data accessibility (0.20), privacy preservation (0.20), regulatory acceptance (0.20), and implementation feasibility (0.15). Real-time data access portals with privacy-preserving analytics achieved the highest TES (0.886) through the best data accessibility (0.920) and privacy preservation (0.920). Individual patient data sharing platforms ranked second (0.877) with strong disclosure completeness (0.900). Registry-based transparency (0.872) remains the regulatory foundation. CSR public summary disclosure (0.861) provides accessible summary information. Blockchain-based immutable records (0.831) offer strong data integrity guarantees but face implementation complexity.